ReviewCureus2025
Association Between Elevated Neutrophil-to-Lymphocyte Ratio and Mortality Risk in Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Article
- Predictors of secondary cardiovascular events in older adults with community-acquired pneumonia: a prospective observational study.Clinics (Sao Paulo, Brazil) · 2026Article
- Biomarker-concordant Steroid use in Hospitalized Patients with Community-acquired Pneumonia: A Prospective Cohort Study.The open respiratory medicine journal · 2026Article
- Risk-stratified surveillance after LEEP: a nomogram integrating HPV persistence, margin status, and clinical factors to predict CIN2+ recurrence.Frontiers in oncology · 2026Article
- Use of Routine Hematological and Biochemical Parameters to Predict Clinical Outcomes in Community-acquired Pneumonia.Saudi journal of medicine & medical sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The neutrophil-to-lymphocyte ratio (NLR), derived from routine complete blood count parameters, has emerged as a potential prognostic biomarker reflecting systemic inflammation and immune dysfunction. This systematic review and meta-analysis evaluated the association between elevated NLR and mortality risk in community-acquired pneumonia (CAP) patients. A comprehensive literature search was conducted across multiple databases from January 2011 to August 2025, identifying studies that measured NLR in adult CAP patients with mortality as an endpoint. Twelve observational studies were included, comprising diverse patient populations across different healthcare settings. Random-effects meta-analysis was performed using R software (R Foundation for Statistical Computing, Vienna, Austria), with relative risk as the primary effect measure. Quality assessment was conducted using the Newcastle-Ottawa Scale. The pooled analysis demonstrated that elevated NLR was significantly associated with increased all-cause mortality risk in CAP patients (RR: 2.02, 95% CI: 1.18-3.47, p<0.05). Patients with high NLR values had approximately twice the risk of death compared to those with lower ratios. Pooled analysis showed that high NLR was associated with increased risk of ICU admission (RR: 1.30, 95% CI: 1.11-1.53). Substantial heterogeneity was observed across studies (I² = 99% for mortality, 85% for ICU admission), likely reflecting variations in patient populations, NLR cutoff values, and clinical settings. Sensitivity analysis confirmed the robustness of findings. This meta-analysis supports NLR as a valuable, cost-effective prognostic biomarker for mortality prediction in CAP patients, potentially enhancing clinical decision-making when integrated with existing severity assessment tools.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.